Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial
M. Kolb (Hamilton, Ontario, Canada), A. Wells (London, United Kingdom), J. Behr (Munich, Germany), L. Richeldi (Rome, Italy), B. Schinzel (Heidelberg, Germany), M. Quaresma (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), G. Raghu (Seattle, Washington, United States of America), F. Martinez (New York, New York, United States of America)
Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias
Session: Clinical news in idiopathic interstitial pneumonias
Session type: Oral Presentation
Number: 546
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kolb (Hamilton, Ontario, Canada), A. Wells (London, United Kingdom), J. Behr (Munich, Germany), L. Richeldi (Rome, Italy), B. Schinzel (Heidelberg, Germany), M. Quaresma (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), G. Raghu (Seattle, Washington, United States of America), F. Martinez (New York, New York, United States of America). Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial. 546
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: